Adlai Nortye Ltd
adlainortye.comWhat Do They Do?
Develops drug candidates for cancer treatment, including RAS-targeting therapies and cancer immunotherapies.
20-F for FY2025, filed Apr 10, 2026We are a global clinical-stage company at the forefront of discovering and developing innovative cancer therapies. Leveraging our dual R&D…View ↗
AN9025 is an oral small molecule pan-RAS(ON) inhibitor with best-in-class potential, designed to target a broad spectrum of RAS mutations…View ↗
AN8025 is a next-generation tri-specific antibody fusion protein derived from an approved αPD-L1 antibody and fused with functionally…View ↗
Who Are Their Customers?
Pharmaceutical and biotechnology partners license rights to drug candidates and related intellectual property directly from Adlai Nortye for development and commercialization.
20-F for FY2025, filed Apr 10, 2026
Do Revenues Turn Into Profits?
No. It lost $35.5M in .
20-F for FY2025, filed Apr 10, 2026
20-F for FY2025, filed Apr 10, 2026
−$35.5MView ↗
Loading...
